BPMC Blueprint Medicines Corp

Nasdaq blueprintmedicines.com


$ 129.50 $ 0.18 (0.14 %)    

Thursday, 17-Jul-2025 16:23:31 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 129.46
$ 129.35
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 73.04 - $ 129.65
2,980,995
na
8.36B
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2025 03-31-2025 10-Q
2 02-13-2025 12-31-2024 10-K
3 10-30-2024 09-30-2024 10-Q
4 08-01-2024 06-30-2024 10-Q
5 05-02-2024 03-31-2024 10-Q
6 02-15-2024 12-31-2023 10-K
7 10-26-2023 09-30-2023 10-Q
8 08-02-2023 06-30-2023 10-Q
9 05-04-2023 03-31-2023 10-Q
10 02-16-2023 12-31-2022 10-K
11 11-01-2022 09-30-2022 10-Q
12 08-02-2022 06-30-2022 10-Q
13 05-03-2022 03-31-2022 10-Q
14 02-17-2022 12-31-2021 10-K
15 10-28-2021 09-30-2021 10-Q
16 07-29-2021 06-30-2021 10-Q
17 04-29-2021 03-31-2021 10-Q
18 02-17-2021 12-31-2020 10-K
19 10-29-2020 09-30-2020 10-Q
20 07-31-2020 06-30-2020 10-Q
21 05-06-2020 03-31-2020 10-Q
22 02-13-2020 12-31-2019 10-K
23 11-05-2019 09-30-2019 10-Q
24 08-01-2019 06-30-2019 10-Q
25 05-09-2019 03-31-2019 10-Q
26 02-26-2019 12-31-2018 10-K
27 10-30-2018 09-30-2018 10-Q
28 08-01-2018 06-30-2018 10-Q
29 05-02-2018 03-31-2018 10-Q
30 02-21-2018 12-31-2017 10-K
31 10-31-2017 09-30-2017 10-Q
32 08-02-2017 06-30-2017 10-Q
33 05-03-2017 03-31-2017 10-Q
34 03-09-2017 12-31-2016 10-K
35 11-10-2016 09-30-2016 10-Q
36 08-09-2016 06-30-2016 10-Q
37 05-10-2016 03-31-2016 10-Q
38 03-11-2016 12-31-2015 10-K
39 11-09-2015 09-30-2015 10-Q
40 08-10-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sanofi-expands-respiratory-vaccine-portfolio-with-uk-biotech-buy

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its ...

 cogents-chronic-immune-disorder-drug-has-strong-potential-to-become-a-blockbuster-analyst

Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end...

 wells-fargo-downgrades-blueprint-medicines-to-equal-weight-lowers-price-target-to-129

Wells Fargo analyst Derek Archila downgrades Blueprint Medicines (NASDAQ:BPMC) from Overweight to Equal-Weight and lowers th...

 wells-fargo-downgrades-blueprint-medicines-to-equal-weight-lowers-price-target-to-129

Wells Fargo analyst Derek Archila downgrades Blueprint Medicines (NASDAQ:BPMC) from Overweight to Equal-Weight and lowers th...

 deal-dispatch-tv-stations-for-sale-this-buyer-wants-seconds-on-pasta

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.

 morgan-stanley-maintains-equal-weight-on-blueprint-medicines-raises-price-target-to-129

Morgan Stanley analyst Judah Frommer maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price ta...

 ubs-maintains-neutral-on-blueprint-medicines-raises-price-target-to-129

UBS analyst David Dai maintains Blueprint Medicines (NASDAQ:BPMC) with a Neutral and raises the price target from $88 to $129.

 citigroup-upgrades-blueprint-medicines-to-neutral-raises-price-target-to-129

Citigroup analyst David Lebowitz upgrades Blueprint Medicines (NASDAQ:BPMC) from Sell to Neutral and raises the price target...

 jmp-securities-downgrades-blueprint-medicines-to-market-perform

JMP Securities analyst Reni Benjamin downgrades Blueprint Medicines (NASDAQ:BPMC) from Market Outperform to Market Perform.

 stephens--co-downgrades-blueprint-medicines-to-equal-weight-lowers-price-target-to-135

Stephens & Co. analyst Sudan Loganathan downgrades Blueprint Medicines (NASDAQ:BPMC) from Overweight to Equal-Weight and...

 wolfe-research-downgrades-blueprint-medicines-to-peer-perform

Wolfe Research analyst Andy Chen downgrades Blueprint Medicines (NASDAQ:BPMC) from Outperform to Peer Perform.

 scotiabank-downgrades-blueprint-medicines-to-sector-perform-announces-135-price-target

Scotiabank analyst Louise Chen downgrades Blueprint Medicines (NASDAQ:BPMC) from Sector Outperform to Sector Perform and ann...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION